Last reviewed 2026-05-22 · How we verify

Ribiciclib

Novartis Pharmaceuticals · Phase 2 active Small molecule ✓ Verified May 2026

Ribiciclib is a Small molecule drug developed by Novartis Pharmaceuticals. It is currently in Phase 2 development.

Ribiciclib is a CDK4/6 inhibitor used to treat metastatic breast cancer. It is studied in real-world settings alongside other CDK4/6 inhibitors such as Palbociclib and Abemaciclib.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Novartis Pharmaceuticals is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Ribiciclib
Sponsor	Novartis Pharmaceuticals
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ribiciclib CI brief — competitive landscape report
Ribiciclib updates RSS · CI watch RSS
Novartis Pharmaceuticals portfolio CI

Frequently asked questions about Ribiciclib

What is Ribiciclib?

Ribiciclib is a Small molecule drug developed by Novartis Pharmaceuticals.

Who makes Ribiciclib?

Ribiciclib is developed by Novartis Pharmaceuticals (see full Novartis Pharmaceuticals pipeline at /company/novartis-pharmaceuticals).

What development phase is Ribiciclib in?

Ribiciclib is in Phase 2.

Manufacturer: Novartis Pharmaceuticals — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing